Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 20.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,000 shares of the biotechnology company's stock after selling 45,000 shares during the quarter. Hudson Bay Capital Management LP owned approximately 0.14% of Arrowhead Pharmaceuticals worth $3,290,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Avoro Capital Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 25.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock worth $208,889,000 after acquiring an additional 2,222,223 shares during the last quarter. Norges Bank acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $38,622,000. Farallon Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $11,821,000. Slate Path Capital LP raised its stake in Arrowhead Pharmaceuticals by 7.1% during the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock worth $98,362,000 after purchasing an additional 347,000 shares during the period. Finally, Balyasny Asset Management L.P. boosted its holdings in shares of Arrowhead Pharmaceuticals by 266.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 372,749 shares of the biotechnology company's stock valued at $7,008,000 after purchasing an additional 270,897 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Up 2.4%

Shares of ARWR traded up $0.37 during midday trading on Friday, hitting $15.71. The company had a trading volume of 1,821,408 shares, compared to its average volume of 1,479,325. The company's 50 day moving average price is $13.29 and its 200 day moving average price is $17.83. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -3.04 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same period in the previous year, the firm posted ($1.02) EPS. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the business's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the completion of the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at $45,055,219.95. This represents a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 275,880 shares of company stock valued at $4,034,037. Insiders own 4.30% of the company's stock.

Analyst Ratings Changes

ARWR has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday. B. Riley restated a "buy" rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Finally, Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.13.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.